Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $18

Wells Fargo analyst Benjamin Burnett maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $50 to $18.